| Year |
Citation |
Score |
| 2021 |
Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do KT, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz RL, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, ... ... Parchment RE, et al. Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33863809 DOI: 10.1158/1078-0432.CCR-21-0329 |
0.332 |
|
| 2020 |
Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, ... ... Parchment RE, et al. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 32314030 DOI: 10.1007/S00280-020-04073-5 |
0.403 |
|
| 2020 |
Naqash AR, Mittra A, O'Sullivan Coyne GH, Chen L, Das B, Kummar S, Do KT, Chang T, Bruns A, Juwara L, Miller B, Kinders RJ, Parchment RE, Rubinstein LV, Ji JJ, et al. Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775). Journal of Clinical Oncology. 38: 3624-3624. DOI: 10.1200/Jco.2020.38.15_Suppl.3624 |
0.393 |
|
| 2020 |
O'Sullivan Coyne GH, Gross AM, Dombi E, Tibery C, Carbonell A, Takebe N, Derdak J, Pichard D, Srivastava AK, Herrick W, Parchment RE, Martin S, Wolters P, Whitcomb P, Rubinstein L, et al. Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). Journal of Clinical Oncology. 38: 3612-3612. DOI: 10.1200/Jco.2020.38.15_Suppl.3612 |
0.351 |
|
| 2020 |
Herrick W, Coyne GO, Gross A, Dombi E, Govindharajulu J, Kilpatrick C, Desanto J, Carbonell AM, Derdak J, Pichard DC, Tibery CM, Wood BJ, Doyle L, Doroshow JH, Chen A, ... Parchment RE, et al. Abstract 805: Intra-tumoral pharmacodynamics of selumetinib in serial biopsies from patients with neurofibroma Cancer Research. 80: 805-805. DOI: 10.1158/1538-7445.Am2020-805 |
0.435 |
|
| 2020 |
Ferry-Galow KV, Wilsker D, Kinders RJ, Makhlouf HR, Dull A, Navas T, Andrews RE, Coyne GO, Chen AP, Doroshow JH, Parchment RE. Abstract 802: Implementation of optimized research biopsy analyses for clinical pharmacodynamic (PD) studies Cancer Research. 80: 802-802. DOI: 10.1158/1538-7445.Am2020-802 |
0.378 |
|
| 2020 |
Benton GJ, Ferry-Galow KV, Lonsberry VE, Mohandoss M, Stotler H, Trail D, Georgius K, Hollingshead M, Wilsker D, Kinders R, Doroshow JH, Parchment RE. Abstract 6495: Development of robust and reproducible controls to support clinical implementation of quantitative immunofluorescence assays for pharmacodynamic biomarkers Epidemiology. 80: 6495-6495. DOI: 10.1158/1538-7445.Am2020-6495 |
0.431 |
|
| 2020 |
Campbell P, Hose C, Touny LE, Harris E, Connelly J, Bonomi C, Dougherty K, Styers S, Walke A, Moyer J, Baldwin M, Wade A, Mullendore M, Arthur K, Murphy M, ... ... Parchment RE, et al. Abstract 3913: Evaluation of patient-derived cell lines and cancer organoids for the prediction of drug responses in patient-derived xenograft models Clinical Trials. DOI: 10.1158/1538-7445.Am2020-3913 |
0.353 |
|
| 2019 |
Navas T, Kinders RJ, Lawrence SM, Ferry-Galow KV, Borgel S, Hollingshead MG, Srivastava AK, Alcoser SY, Makhlouf HR, Chuaqui R, Wilsker DF, Konaté MM, Miller SB, Voth AR, Chen L, ... ... Parchment RE, et al. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Cancer Research. PMID 31732654 DOI: 10.1158/0008-5472.Can-18-3539 |
0.413 |
|
| 2019 |
Wilsker DF, Barrett AM, Dull AB, Lawrence SM, Hollingshead MG, Chen A, Kummar S, Parchment RE, Doroshow JH, Kinders RJ. Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30792217 DOI: 10.1158/1078-0432.Ccr-18-2523 |
0.381 |
|
| 2019 |
Herrick W, Kilpatrick C, Esposito D, Stotler H, Hollingshead MG, Doroshow JH, Parchment RE, Srivastava AK. Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies. Journal of Clinical Oncology. 37: 3134-3134. DOI: 10.1200/Jco.2019.37.15_Suppl.3134 |
0.428 |
|
| 2019 |
Navas T, Srivastava AK, Govindharajulu JP, Evrard YA, Borgel S, Carter J, Chen L, Das B, Divelbiss R, Karlovich C, Patidar R, Radzyminski M, Stottlemyer J, Williams PM, Hollingshead MG, ... ... Parchment RE, et al. Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors. Journal of Clinical Oncology. 37: 3131-3131. DOI: 10.1200/Jco.2019.37.15_Suppl.3131 |
0.402 |
|
| 2019 |
Mittra A, O'Sullivan Coyne GH, Do KT, Piha-Paul SA, Kummar S, Takebe N, Bruns A, Juwara L, Rubinstein L, Hogu M, Kinders RJ, Parchment RE, Miller B, Wilsker D, Monge B. MC, et al. Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors. Journal of Clinical Oncology. 37: 3067-3067. DOI: 10.1200/Jco.2019.37.15_Suppl.3067 |
0.432 |
|
| 2019 |
Navas T, Fino K, Fung KL, Cutuli F, Kinders RJ, Sharma A, O'Sullivan-Coyne G, Chen AP, Hecht TT, Doroshow JH, Parchment RE. A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues. Journal of Clinical Oncology. 37: 2629-2629. DOI: 10.1200/Jco.2019.37.15_Suppl.2629 |
0.383 |
|
| 2019 |
Al-Katib A, Kuzel TM, Parchment R. A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma Blood. 134: 4041-4041. DOI: 10.1182/Blood-2019-127278 |
0.429 |
|
| 2019 |
Coyne GO, Khan SS, Conlon K, Streicher H, Bruns A, Piekarz R, Takebe N, Juwara L, Parchment R, Navas T, Fino K, Fung KL, Sharon E, Doroshow JH, Waldmann TA, et al. Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-015 |
0.449 |
|
| 2019 |
Coyne GO, Bonilla CM, Zlott J, Takebe N, Meehan R, Juwara L, Piekarz R, Rubinstein L, Wilsker DF, Kinders RJ, Parchment RE, Jiwani S, Kumar S, Doroshow JH, Chen AP. Abstract LB-293: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-293 |
0.392 |
|
| 2019 |
Mittra A, Coyne GO, Kummar S, Do K, Bruns A, Juwara L, Piekarz R, Rubinstein L, Prindiville S, Sharon E, Streicher H, Hsia T, Mugundu G, Ji J, Wilsker D, ... ... Parchment R, et al. Abstract CT099: DNA damage response and therapeutic activity following once-daily administration of the Wee 1 inhibitor AZD1775 (adavosertib) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct099 |
0.463 |
|
| 2019 |
Touny LE, Harris E, Hose C, Connelly J, Vengsarkar D, Monks A, Parchment RE, Doroshow JH, Teicher BA, Rapisarda A. Abstract 270: Temozolomide resistant MGMT negative/MMR proficient cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival Cancer Research. 79: 270-270. DOI: 10.1158/1538-7445.Am2019-270 |
0.39 |
|
| 2019 |
Coyne GO, Gross A, Dombi E, DeSanto J, Carbonell A, Derdak J, Pichard D, Wood B, Tibery C, Wolters P, Whitcomb T, Martin S, Bradford D, Srivastava A, Herrick W, ... Parchment R, et al. Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Pr07 |
0.372 |
|
| 2019 |
Coyne GO, Kummar S, Zlott J, Juwara L, Takebe N, Hogu M, Anderson L, Collins J, Piekarz R, Streicher H, Sharon E, Mittra A, Khan S, Miller B, Navas T, ... ... Parchment R, et al. Abstract C008: Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C008 |
0.469 |
|
| 2019 |
Coyne GO, Yap TA, Moore N, Mittra A, Takebe N, Juwara L, Khan S, Dumbrava EI, Streicher H, Piekarz R, Sharon E, Meric-Bernstam F, Parchment R, Navas T, Fung KL, et al. Abstract B105: Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B105 |
0.453 |
|
| 2019 |
Wang L, Miller B, Khin S, O’Sullivan-Coyne G, Chen AP, Kummar S, Takebe N, Ferry-Galow K, Parchment RE, Rubinstein L, Piekarz R, Newman EM, Doroshow JH, Kinders RJ. Abstract B018: Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B018 |
0.433 |
|
| 2019 |
Khan SS, O'Sullivan G, Rubinstein L, Kummar S, Juwara L, Zlott J, Mittra A, Hogu M, Collins J, Srivastava A, Miller B, Parchment RE, Hourigan CS, Pavletic S, Doroshow J, et al. Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A071 |
0.503 |
|
| 2019 |
Navas T, Kinders RJ, Makhlouf H, Lawrence SM, Chuaqui R, Fino K, Dull A, Ferry-Galow K, Wilsker D, Chen AP, Kummar S, Parchment RE, Doroshow JH. Abstract A050: Validation of β-catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsy specimens Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A050 |
0.358 |
|
| 2018 |
Burton JH, Mazcko CN, LeBlanc AK, Covey JM, Ji JJ, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana SE, Weishaar K, London CA, Kisseberth WC, Krick E, Vail DM, et al. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30061364 DOI: 10.1158/1078-0432.Ccr-18-1498 |
0.354 |
|
| 2018 |
Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, ... ... Parchment RE, et al. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. Plos One. 13: e0199361. PMID 29928062 DOI: 10.1371/Journal.Pone.0199361 |
0.392 |
|
| 2018 |
Dull AB, Wilsker D, Hollingshead M, Mazcko C, Annunziata CM, LeBlanc AK, Doroshow JH, Kinders RJ, Parchment RE. Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget. 9: 17104-17116. PMID 29682208 DOI: 10.18632/Oncotarget.24936 |
0.404 |
|
| 2018 |
Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics. PMID 29444985 DOI: 10.1158/1535-7163.Mct-17-0552 |
0.448 |
|
| 2018 |
Parchment RE, Navas T, Fino K, Fung A, Cutuli F, Wang L, Kinders RJ, Doroshow JH. T cell receptor activation status as biological context for interpreting PD1/PDL1 biomarker measurements. Journal of Clinical Oncology. 36: 54-54. DOI: 10.1200/Jco.2018.36.5_Suppl.54 |
0.347 |
|
| 2018 |
Srivastava AK, Govindharajulu JP, Hollingshead MG, Moore WJ, Tomaino F, Banfield K, Lee T, Olejniczak ET, Sensintaffar J, Millin MD, Parchment RE, Doroshow JH, Fesik S. BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness. Journal of Clinical Oncology. 36: 2582-2582. DOI: 10.1200/Jco.2018.36.15_Suppl.2582 |
0.349 |
|
| 2018 |
O'Sullivan Coyne GH, Do KT, Kummar S, Takebe N, Quinn MF, Piha-Paul SA, Bruns A, Juwara L, Sharon E, Piekarz R, Streicher H, Rubinstein L, Wilsker D, Kinders RJ, Parchment RE, et al. Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 2549-2549. DOI: 10.1200/Jco.2018.36.15_Suppl.2549 |
0.361 |
|
| 2018 |
Nevo E, Hollingshead MG, Ferry-Galow K, Govindharajulu JP, Nevo S, Gray KD, Parchment RE, Doroshow JH, Srivastava AK. Abstract 4537: Cryogenic biopsy device for preservation of labile biomarkers Cancer Research. 78: 4537-4537. DOI: 10.1158/1538-7445.Am2018-4537 |
0.321 |
|
| 2018 |
Herrick WG, Kilpatrick CL, Hollingshead M, Doroshow JH, Parchment RE, Srivastava AK. Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B081 |
0.346 |
|
| 2018 |
Evans DM, Michael SH, Bowles L, Delosh RM, Julie L, Ogle CC, Russell R, Thomas S, Parchment R, Doroshow J, Teicher B. Abstract A150: Complex 3D cultures for combination compound screens reveal new insights Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A150 |
0.44 |
|
| 2018 |
Touny LHE, Connelly J, Hose C, Monks A, Newton D, Stockwin L, Hollingshead M, Parchment R, Doroshow JH, Teicher BA, Rapisarda A. Abstract A117: Modeling ATM loss of function via CRISPR-Cas9 as a predictive tool for therapeutic responses in cancer cells Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A117 |
0.426 |
|
| 2018 |
Touny LHE, Harris E, Hose C, Connelly J, Monks A, Newton D, Stockwin L, Hollingshead M, Parchment R, Doroshow JH, Teicher BA, Rapisarda A. Abstract A116: Temozolomide-resistant MGMT/MSI double-negative cancer cells rely on ATR signaling and homologous recombination for DNA repair and survival Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A116 |
0.383 |
|
| 2018 |
Navas T, Srivastava AK, Ferry-Galow K, Makhlouf H, Chuaqui R, Kinders RJ, Bottaro DP, Chen AP, Parchment RE, Kummar S, Doroshow JH. Abstract A002: Evidence of pazopanib-induced epithelial-mesenchymal transition (EMT) in human tumors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A002 |
0.415 |
|
| 2017 |
Teicher BA, Silvers T, Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Parchment R, Krushkal J, Sonkin D, Rubinstein L, Morris J, Evans D. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. Cancer Medicine. PMID 28766886 DOI: 10.1002/Cam4.1131 |
0.324 |
|
| 2017 |
Balasubramanian P, Kinders RJ, Kummar S, Gupta V, Hasegawa D, Menachery A, Lawrence SM, Wang L, Ferry-Galow K, Davis D, Parchment RE, Tomaszewski JE, Doroshow JH. Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system. Plos One. 12: e0175414. PMID 28403214 DOI: 10.1371/Journal.Pone.0175414 |
0.378 |
|
| 2017 |
Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE. Effective implementation of novel MET pharmacodynamic assays in translational studies. Annals of Translational Medicine. 5: 3. PMID 28164088 DOI: 10.21037/Atm.2016.12.78 |
0.457 |
|
| 2017 |
Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM. Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. Plos One. 12: e0171582. PMID 28158293 DOI: 10.1371/Journal.Pone.0171582 |
0.361 |
|
| 2017 |
O'Sullivan Coyne GH, Kummar S, Meehan RS, Juwara L, Piekarz R, Sharon E, Streicher H, Conley BA, Takebe N, Harris L, Doyle A, Quinn MF, Rubinstein L, Wilsker D, Kinders RJ, ... Parchment RE, et al. Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 35: TPS2609-TPS2609. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2609 |
0.463 |
|
| 2017 |
Parchment RE, Ferry-Galow K, Makhlouf HR, Wood BJ, Levy EB, Krishnasamy VP, Chang R, O'Sullivan Coyne GH, Meehan RS, Kinders RJ, Doroshow JH, Chen AP. Suitability factors of core needle biopsies for pharmacodynamic (PD) studies. Journal of Clinical Oncology. 35: 2540-2540. DOI: 10.1200/Jco.2017.35.15_Suppl.2540 |
0.408 |
|
| 2017 |
Kinders RJ, Dull AB, Wilsker D, LeBlanc A, Mazcko C, Hollingshead MG, Parchment RE, Doroshow JH. Antitumor activity of indenoisoquinoline inhibitors of topoisomerase 1 (TOP1) via apoptosis and autophagocytosis pathways in animal models. Journal of Clinical Oncology. 35: 11588-11588. DOI: 10.1200/Jco.2017.35.15_Suppl.11588 |
0.406 |
|
| 2017 |
Navas T, Hollingshead MG, Borgel S, Carter JP, Millione A, Gouker BA, Butcher D, Holbeck S, Srivastava AK, Kinders RJ, Bottaro DP, Kumar S, Chen A, Doroshow JH, Parchment RE. Abstract 845: A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics Cancer Research. 77: 845-845. DOI: 10.1158/1538-7445.Am2017-845 |
0.448 |
|
| 2017 |
Meehan RS, Chen AP, Coyne GO, Kummar S, Ji J, Vilimas R, Juwara L, Kinders RJ, Ferry-Galow K, Wilsker D, Zhang Y, Dull AB, Navas T, Wang L, Parchment RE, et al. Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations Cancer Research. 77: 4678-4678. DOI: 10.1158/1538-7445.Am2017-4678 |
0.466 |
|
| 2017 |
Dull AB, Wilsker D, Kinders RJ, Parchment RE, Evans D, Teicher BA, Doroshow JH. Abstract 3072: A clinical pharmacodynamic biomarker assay that distinguishes potentially repairable, cytotoxic drug-induced DNA double strand breaks (DSBs) from DSBs associated with apoptotic cell death Cancer Research. 77: 3072-3072. DOI: 10.1158/1538-7445.Am2017-3072 |
0.425 |
|
| 2016 |
Parchment RE, Doroshow JH. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Seminars in Oncology. 43: 514-25. PMID 27663483 DOI: 10.1053/J.Seminoncol.2016.07.002 |
0.384 |
|
| 2016 |
Parchment RE, Voth AR, Doroshow JH, Berzofsky JA. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Seminars in Oncology. 43: 501-13. PMID 27663482 DOI: 10.1053/J.Seminoncol.2016.06.008 |
0.414 |
|
| 2016 |
Ferry-Galow KV, Ji J, Kinders RJ, Zhang Y, Czambel RK, Schmitz JC, Herzog J, Evrard YA, Parchment RE. Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay. Seminars in Oncology. 43: 492-500. PMID 27663481 DOI: 10.1053/J.Seminoncol.2016.06.007 |
0.379 |
|
| 2016 |
Ferry-Galow KV, Makhlouf HR, Wilsker DF, Lawrence SM, Pfister TD, Marrero AM, Bigelow KM, Yutzy WH, Ji JJ, Butcher DO, Gouker BA, Kummar S, Chen AP, Kinders RJ, Parchment RE, et al. The root causes of pharmacodynamic assay failure. Seminars in Oncology. 43: 484-91. PMID 27663480 DOI: 10.1053/J.Seminoncol.2016.06.006 |
0.408 |
|
| 2016 |
Parchment RE, Doroshow JH. Theory and practice of clinical pharmacodynamics in oncology drug development. Seminars in Oncology. 43: 427-35. PMID 27663474 DOI: 10.1053/J.Seminoncol.2016.07.001 |
0.378 |
|
| 2016 |
Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, ... ... Parchment R, et al. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 27169793 DOI: 10.1007/S00280-016-2998-6 |
0.42 |
|
| 2016 |
LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville E, Boerner S, Smith D, Pilat MJ, Zhang J, Tolaney S, Cleary JM, Chen A, Rubinstein L, Boerner JL, Bowditch A, ... ... Parchment RE, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase inhibitor veliparib with irinotecan in patients with advanced tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26842236 DOI: 10.1158/1078-0432.Ccr-15-0652 |
0.418 |
|
| 2016 |
Meehan RS, Chen AP, O'Sullivan Coyne GH, Collins JM, Kummar S, Anderson L, Ishii K, Zlott J, Rubinstein L, Horneffer Y, Juwara L, Jeong W, Takebe N, Kinders RJ, Parchment RE, et al. A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas. Journal of Clinical Oncology. 34: 2556-2556. DOI: 10.1200/Jco.2016.34.15_Suppl.2556 |
0.422 |
|
| 2016 |
Srivastava AK, Govindharajulu JP, Park SR, Navas T, Ferry-Galow KV, Kinders RJ, Lee YH, Bottaro DP, Wright JJ, Hollingshead MG, Chen AP, Parchment RE, Kummar S, Doroshow JH. Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors. Journal of Clinical Oncology. 34: 2553-2553. DOI: 10.1200/Jco.2016.34.15_Suppl.2553 |
0.396 |
|
| 2016 |
Wilsker D, Marrero AM, Dull A, Pfister TD, Lawrence SM, Carter J, Gottholm-Ahalt M, Hollingshead M, Doroshow J, Parchment RE, Kinders RJ. Abstract B24: Ataxia-telangiectasia and Rad3-related (ATR) phosphorylation as a pharmacodynamic biomarker of ATR activation in solid tumor tissue models Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-B24 |
0.505 |
|
| 2016 |
Evans DM, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Thomas S, Kinders R, Navas T, Lawrence S, Monks A, Rapisarda A, Parchment RE, Doroshow JH, Teicher B. Abstract 606: Similar 3D pharmacodynamic (3D-PD) responses of human tumor spheroids and xenografts to topoisomerase 1 inhibitor-induced DNA damage Cancer Research. 76: 606-606. DOI: 10.1158/1538-7445.Am2016-606 |
0.42 |
|
| 2016 |
Evans DM, Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Silvers T, Parchment RE, Teicher B. Abstract 605: Building better cell models for screening oncology compounds Cancer Research. 76: 605-605. DOI: 10.1158/1538-7445.Am2016-605 |
0.345 |
|
| 2016 |
Touny LHe, Connelly J, Hose C, Monks A, Burkett MW, Harris E, Delosh RM, Laudeman J, Ogle C, Reinhart R, Selby M, Silvers T, Evans D, Newton D, Stockwin L, ... ... Parchment R, et al. Abstract 5178: Determinants of response to temozolomide in an exceptionally sensitive patient derived model Cancer Research. 76: 5178-5178. DOI: 10.1158/1538-7445.Am2016-5178 |
0.422 |
|
| 2016 |
O'Sullivan Coyne G, Chen A, Kummar S, Collins J, Meehan R, Suto M, Rubinstein L, Kinders R, Moore N, Parchment R, Horneffer Y, Juwara L, Difilippantonio M, Piekarz R, Doroshow J. First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors Annals of Oncology. 27: vi133. DOI: 10.1093/Annonc/Mdw368.54 |
0.355 |
|
| 2016 |
Ferry-Galow K, Makhlouf H, Kinders R, Chen A, Doroshow J, Parchment R. Suitability of post-diagnostic core needle tumor biopsies for correlative studies of molecular drug action (pharmacodynamics) European Journal of Cancer. 69: S65-S66. DOI: 10.1016/S0959-8049(16)32784-8 |
0.357 |
|
| 2015 |
Guo L, Hamre J, Davis M, Parchment RE. Human CD34(+) progenitor hematopoiesis in liquid culture for in vitro assessment of drug-induced myelotoxicity. Toxicology in Vitro : An International Journal Published in Association With Bibra. PMID 26616282 DOI: 10.1016/J.Tiv.2015.11.017 |
0.314 |
|
| 2015 |
Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Govindharajulu JP, Layhee A, Damour E, Donohue J, Esposito D, Mapes JP, Kinders R, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, ... Parchment RE, et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446940 DOI: 10.1158/1078-0432.Ccr-14-3156 |
0.376 |
|
| 2015 |
Ji JJ, Zhang Y, Redon CE, Chen A, Holbeck S, Hollingshead MG, Parchment RE, Pommier Y, Tomaszewski JE, Doroshow JH, Bonner W. Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure. Journal of Clinical Oncology. 33: 2559-2559. DOI: 10.1200/Jco.2015.33.15_Suppl.2559 |
0.424 |
|
| 2015 |
LoRusso PM, Tolaney SM, Wong S, Parchment RE, Kinders RJ, Wang L, Aldrich J, Chen A, Durecki D, Boerner SA, Guthrie T, Bowditch A, Heilbrun LK, Pilat MJ, Craig D, et al. Abstract CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct325 |
0.432 |
|
| 2015 |
Ferry-Galow KV, Lawrence SM, Navas T, Makhlouf HR, Butcher DO, Gouker BA, Yutzy WH, Ji J, Kinders R, Parchment RE, Kummar S, Tomaszewski JE, Doroshow JH. Abstract 5279: Establishing robust pharmacodynamic (PD) immunofluorescence assays of clinical biopsies at the National Cancer Institute: Optimized quality control procedures for the evaluation of DNA damage response and epithelial-mesenchymal transition (EMT) biomarkers Cancer Research. 75: 5279-5279. DOI: 10.1158/1538-7445.Am2015-5279 |
0.34 |
|
| 2015 |
Navas T, Pfister TD, Lawrence SM, Srivastava AK, Kinders RJ, Borgel S, Alcoser S, Hollingshead MG, Dutko LM, Gouker BA, Butcher D, Ng-Eaton E, Takebe N, Lee YH, Bottaro DP, ... Parchment RE, et al. Abstract 5082: Impact of HGF knockin microenvironment on epithelial-mesenchymal transition and cancer stem cells in a non-small cell lung cancer xenograft model Cancer Research. 75: 5082-5082. DOI: 10.1158/1538-7445.Am2015-5082 |
0.402 |
|
| 2015 |
Wang L, Owusu F, Khin S, Parchment R, Chen A, Kummar S, Doroshow JH, Kinders RJ. Abstract LB-B20: Characterization and Enumeration of Multiple Circulating Tumor Cell Phenotypes Using Two Distinct Platforms Establishes Presence of Epithelial-Mesenchymal Transition CTCs in Patients Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B20 |
0.434 |
|
| 2015 |
Navas T, Kinders RJ, Lawrence SM, Ferry-Galow K, Pfister TD, Srivastava AK, Alcoser SY, Hollingshead MG, Dutko LM, Gouker BA, Butcher DO, Makhlouf H, Chuaqui R, Bottaro DP, Kummar S, ... ... Parchment RE, et al. Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B18 |
0.393 |
|
| 2014 |
Kinders R, Ferry-Galow K, Wang L, Srivastava AK, Ji JJ, Parchment RE. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2578-86. PMID 24831280 DOI: 10.1158/1078-0432.Ccr-14-0476 |
0.369 |
|
| 2014 |
Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH. Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues. Analytical Biochemistry. 459: 1-11. PMID 24799347 DOI: 10.1016/J.Ab.2014.04.025 |
0.341 |
|
| 2014 |
Wilsker DF, Marrero AM, Hollingshead M, Lawrence SM, Chen A, Kummar S, Covey JM, Parchment RE, Kinders RJ, Tomaszewski JE, Doroshow JH. Abstract 4689: Pre-clinical investigation of the wee1 inhibitor MK-1775 using pharmacodynamic and mechanistic markers in diverse cancer modelsin vivo Cancer Research. 74: 4689-4689. DOI: 10.1158/1538-7445.Am2014-4689 |
0.444 |
|
| 2014 |
Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Peggins J, Bottaro DP, Wright JJ, Kinders RJ, Tomaszewski JE, Doroshow JH, Parchment RE. Abstract 3691: Met target inhibition-guided efficacy in preclinical models Cancer Research. 74: 3691-3691. DOI: 10.1158/1538-7445.Am2014-3691 |
0.491 |
|
| 2014 |
Balasubramanian P, Wang L, Lawrence SM, Navas T, Kummar S, Hollingshead M, Owusu F, Parchment RE, Tomaszewski JE, Doroshow JH, Kinders RJ. Abstract 3062: Isolation and characterization of circulating tumor cells (CTCs) from peripheral blood specimens of patients with advanced solid tumor malignancies (using ApoStream™ instrumentation) Cancer Research. 74: 3062-3062. DOI: 10.1158/1538-7445.Am2014-3062 |
0.395 |
|
| 2014 |
Navas T, Lawrence SL, Butcher D, Dutko LM, Hollingshead MG, Kinders RJ, Parchment RE, Bottaro DP, Linehan WM, Tomaszewski JE, Srivastava AK, Doroshow JH. Abstract 1049: Quantitative immunofluorescence assessment of MET and epithelial to mesenchymal transition (EMT) biomarker modulation by antiangiogenic inhibitors in xenograft tumor tissues Cancer Research. 74: 1049-1049. DOI: 10.1158/1538-7445.Am2014-1049 |
0.414 |
|
| 2013 |
Kaur G, Behrsing H, Parchment RE, Millin MD, Teicher BA. Analyses of the combination of 6-MP and dasatinib in cell culture. International Journal of Oncology. 43: 13-22. PMID 23652925 DOI: 10.3892/Ijo.2013.1930 |
0.428 |
|
| 2013 |
Behrsing HP, Furniss MJ, Davis M, Tomaszewski JE, Parchment RE. In vitro exposure of precision-cut lung slices to 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride (NSC 710305, Phortress) increases inflammatory cytokine content and tissue damage. Toxicological Sciences : An Official Journal of the Society of Toxicology. 131: 470-9. PMID 23143926 DOI: 10.1093/Toxsci/Kfs319 |
0.34 |
|
| 2013 |
Parchment RE, Kinders RJ, Ji JJ, Srivastava AK, Ferry-Galow KV, Tomaszewski JE, Doroshow JH. Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Clinical implementation of a PAR immunoassay in tumor biopsies. Journal of Clinical Oncology. 31: e22080-e22080. DOI: 10.1200/Jco.2013.31.15_Suppl.E22080 |
0.351 |
|
| 2013 |
Srivastava AK, Hollingshead MG, Weiner J, Covey JM, Liston D, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Tomaszewski JE, Parchment RE, Doroshow JH. Application of MET pharmacodynamic assays to compare effectiveness of five MET inhibitors to engage target in tumor tissue. Journal of Clinical Oncology. 31: 11103-11103. DOI: 10.1200/Jco.2013.31.15_Suppl.11103 |
0.43 |
|
| 2013 |
Pfister TD, Dieckman LJ, Kinders RJ, Book A, Colantonio S, Mutreja K, Lawrence SM, Aziz A, Hiltke T, Whiteley G, Parchment RE, Tomaszewski JE, Weinberg RA, Doroshow JH. Abstract 5544: Development of recombinant transcription factor proteins and antibodies for application in clinical immunoassays. Cancer Research. 73: 5544-5544. DOI: 10.1158/1538-7445.Am2013-5544 |
0.371 |
|
| 2013 |
Srivastava AK, Jaganathan S, Stephen LL, Hollingshead MG, Scull J, Kinders RJ, Damour E, Donohue J, Layhee A, Mapes J, Esposito D, Tomaszewski JE, Parchment RE, Doroshow JH. Abstract 3366: Progress on development of multiplex panel of 15 biomarkers to support development of anticancer drugs targeting apoptosis. Cancer Research. 73: 3366-3366. DOI: 10.1158/1538-7445.Am2013-3366 |
0.349 |
|
| 2013 |
Marrero AM, Lawrence SM, Wilsker D, Balasubramanian P, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. Abstract 3341: Development of a multiplex quantitative immunofluorescence assay to evaluate DNA damage repair deficient models in vitro and in vivo and the response to cytotoxic agents. Cancer Research. 73: 3341-3341. DOI: 10.1158/1538-7445.Am2013-3341 |
0.397 |
|
| 2013 |
Balakrishnan MP, Parchment RE, Hollingshead MG, Tomaszewski JE, Kinders RJ, Doroshow JH, Srivastava AK. Abstract 1858: Development of a multiplex panel of biomarkers to assess energy metabolism in cancer. Cancer Research. 73: 1858-1858. DOI: 10.1158/1538-7445.Am2013-1858 |
0.372 |
|
| 2013 |
Navas T, Kinders RJ, Mutreja K, Lawrence SM, Butcher D, Hollingshead M, Parchment RE, Tomaszewski JE, Doroshow JH. Abstract 1500: Development of a Quantitative Immunofluorescence imaging assay to assess β-catenin translocation and multiplex biomarkers for Epithelial-Mesenchymal Transition (EMT) in tumor tissues. Cancer Research. 73: 1500-1500. DOI: 10.1158/1538-7445.Am2013-1500 |
0.386 |
|
| 2013 |
Wang LH, Kummar S, Pfister TD, Balasubramanian P, Parchment RE, Tomaszewski JE, Doroshow JH, Kinders RJ. Abstract 1472: Assessment of CTC-based pharmacodynamic biomarkers in NCI clinical trials of targeted anticancer therapeutics. Cancer Research. 73: 1472-1472. DOI: 10.1158/1538-7445.Am2013-1472 |
0.488 |
|
| 2013 |
Parchment RE, Kinders RJ, Park SR, Ferry-Galow KV, Evrard YA, Ji J, Kummar S, Tomaszewski JE, Doroshow JH. Abstract 1186: Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: clinical implementation of a HIF1α immunoassay in tumor biopsies. Cancer Research. 73: 1186-1186. DOI: 10.1158/1538-7445.Am2013-1186 |
0.378 |
|
| 2013 |
Ferry-Galow KV, Navas T, Lawrence SM, Mutreja K, Butcher D, Hollingshead M, Parchment R, Tomaszewski JE, Doroshow JH, Kinders RJ. Abstract 1173: Development of calibrators and controls as quality control tools for clinical implementation of quantitative immunofluorescence assays for pharmacodynamic biomarkers of molecular targeted agents in tumor biopsies. Cancer Research. 73: 1173-1173. DOI: 10.1158/1538-7445.Am2013-1173 |
0.438 |
|
| 2013 |
Marrero AM, Wilsker D, Lawrence SM, Pfister TD, Hirt J, Parchment RE, Tomaszewski JE, Doroshow JH, Kinders RJ. Abstract PR11: Use of a DNA damage multiplex immunofluorescence assay to monitor pharmacodynamic markers following in vitro exposure to therapeutic agents. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr11 |
0.4 |
|
| 2013 |
Pfister TD, Ferry-Galow KV, Mohabbat T, Kinders RJ, Khanna C, Mazcko C, Parchment RE, Pommier Y, Tomaszewski JE, Doroshow JH. Abstract C278: Topoisomerase 1 immunoassay provides proof of target engagement by the indenoisoquinoline class of topoisomerase 1 inhibitors in canine lymphomas. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C278 |
0.488 |
|
| 2013 |
Balasubramanian P, Wang L, Kummar S, Hollingshead M, Owusu F, Parchment RE, Tomaszewski JE, Doroshow JH, Kinders RJ. Abstract C197: Fluorescent in situ hybridization confirmation of circulating alveolar soft part sarcoma cells (CTCs) isolated from peripheral blood specimens using ApoStream™ instrumentation. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C197 |
0.388 |
|
| 2013 |
Parchment RE, Ferry-Galow K, Ji J, Zhang Y, Pfister TD, Kinders RJ, Evrard YA, Kummar S, Tomaszewski JE, Doroshow JH. Abstract A214: Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Improved performance of the Top1 immunoassay for analysis of tumor biopsies. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A214 |
0.413 |
|
| 2012 |
Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, et al. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. Plos One. 7: e50494. PMID 23284638 DOI: 10.1371/Journal.Pone.0050494 |
0.418 |
|
| 2012 |
Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in using PARP inhibitors to treat cancer. Bmc Medicine. 10: 25. PMID 22401667 DOI: 10.1186/1741-7015-10-25 |
0.364 |
|
| 2012 |
Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, ... ... Parchment RE, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1726-34. PMID 22307137 DOI: 10.1158/1078-0432.Ccr-11-2821 |
0.499 |
|
| 2012 |
Parchment RE, Pessina A. Topoisomerase I inhibitors and drug resistance. Cytotechnology. 27: 149-64. PMID 19002789 DOI: 10.1023/A:1008008719699 |
0.38 |
|
| 2012 |
Doroshow JH, Ji JJ, Chen A, Allen D, Zhang Y, Lawrence SM, Pfister TD, Wang L, Redon CE, Bonner W, Speranza G, Weil MK, Eiseman J, Holleran JL, Kinders RJ, ... ... Parchment RE, et al. Proof of mechanism (POM) in the first-in-human trial of two novel indenoisoquinoline, non-camptothecin topoisomerase I (TOP1) inhibitors. Journal of Clinical Oncology. 30: 3031-3031. DOI: 10.1200/Jco.2012.30.15_Suppl.3031 |
0.425 |
|
| 2012 |
Srivastava AK, Hollingshead MH, Weiner J, Park SR, Kinders RJ, Kummar S, Tomaszewski J, Parchment RE, Doroshow JH. Abstract 3672: Preclinical assessment of MET modulation by a VEGFR inhibitor/MET inhibitor combination that shows additive antitumor efficacy Cancer Research. 72: 3672-3672. DOI: 10.1158/1538-7445.Am2012-3672 |
0.306 |
|
| 2012 |
Marrero AM, Lawrence SM, Balasubramanian P, Pommier YG, Tomaszewski JE, Parchment RE, Doroshow JH, Kinders RJ. Abstract 3620: A multiplex quantitative immunofluorescence assay for DNA damage repair in response to cytotoxic treatment Cancer Research. 72: 3620-3620. DOI: 10.1158/1538-7445.Am2012-3620 |
0.389 |
|
| 2012 |
Park SR, Kinders RJ, Khin S, Hollingshead M, Parchment RE, Tomaszewski JE, Doroshow JH. Abstract 3616: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens Cancer Research. 72: 3616-3616. DOI: 10.1158/1538-7445.Am2012-3616 |
0.398 |
|
| 2012 |
Parchment R, Kinders R, Ji J, Srivastava A, Ferry-Galow K, Tomaszewski J, Doroshow J. 493 Creating Clinical Target Validation Groups Via Quality Assured Transfer of Robust Clinical Pharmacodynamic (PD) Assays From the National Cancer Institute European Journal of Cancer. 48: 153. DOI: 10.1016/S0959-8049(12)72291-8 |
0.34 |
|
| 2011 |
Srivastava AK, Hollingshead MG, Weiner J, Khin S, Borgel S, Risbood P, Pfister TD, Lawrence SM, Kinders RJ, Bottaro DP, Tomaszewski JE, Parchment RE, Doroshow JH. Development and validation of biomarker assays to assess pharmacodynamic modulation of MET. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3042. PMID 28022620 DOI: 10.1200/Jco.2011.29.15_Suppl.3042 |
0.365 |
|
| 2011 |
LoRusso P, Ji JJ, Li J, Heilbrun LK, Shapiro G, Sausville EA, Boerner SA, Smith DW, Pilat MJ, Zhang J, Chen AP, Nechiporchik N, Parchment RE. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3000. PMID 28022181 DOI: 10.1200/Jco.2011.29.15_Suppl.3000 |
0.41 |
|
| 2011 |
Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. Plos One. 6: e26152. PMID 22028822 DOI: 10.1371/Journal.Pone.0026152 |
0.413 |
|
| 2011 |
Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Research. 71: 5626-34. PMID 21795476 DOI: 10.1158/0008-5472.Can-11-1227 |
0.496 |
|
| 2011 |
Ji J, Lee MP, Kadota M, Zhang Y, Parchment RE, Tomaszewski JE, Doroshow JH. Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201 Cancer Research. 71: 4527-4527. DOI: 10.1158/1538-7445.Am2011-4527 |
0.473 |
|
| 2011 |
Kinders RJ, Park SR, Khin S, Hollingshead MG, Parchment RE, Tomaszewski JE, Doroshow JH. Abstract C3: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C3 |
0.422 |
|
| 2011 |
Ji J, Zhang Y, Kinders R, Redon C, Solier S, Agama K, Pommier Y, Bonner W, Hollingshead M, Rubinstein L, Chen A, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH. Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A46 |
0.393 |
|
| 2011 |
Kinders RJ, Wang L, Kummar S, Khin S, Balasubramanian P, Zhu W, Parchment RE, Newman E, Tomaszewski JE, Doroshow JH. Abstract A106: Investigation of 5-fluorodeoxycytidine with tetrahydrouracil as a demethylation regimen in solid tumors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A106 |
0.455 |
|
| 2010 |
Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5447-57. PMID 20924131 DOI: 10.1158/1078-0432.Ccr-09-3076 |
0.383 |
|
| 2010 |
Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4532-42. PMID 20823146 DOI: 10.1158/1078-0432.Ccr-10-0523 |
0.397 |
|
| 2010 |
Pessina A, Bonomi A, Cavicchini L, Albella B, Cerrato L, Parent-Massin D, Sibiril Y, Parchment R, Behrsing H, Verderio P, Pizzamiglio S, Giangreco M, Baglio C, Coccè V, Sisto F, et al. Prevalidation of the rat CFU-GM assay for in vitro toxicology applications. Alternatives to Laboratory Animals : Atla. 38: 105-17. PMID 20507183 DOI: 10.1177/026119291003800212 |
0.365 |
|
| 2010 |
Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH. The statistics of phase 0 trials. Statistics in Medicine. 29: 1072-6. PMID 20419759 DOI: 10.1002/Sim.3840 |
0.376 |
|
| 2010 |
Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1745-55. PMID 20215558 DOI: 10.1158/1078-0432.Ccr-09-2167 |
0.373 |
|
| 2010 |
Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN, Pommier Y. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Research. 70: 2191-203. PMID 20215517 DOI: 10.1158/0008-5472.Can-09-3528 |
0.316 |
|
| 2010 |
Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1073-84. PMID 20103672 DOI: 10.1158/1078-0432.Ccr-09-2799 |
0.436 |
|
| 2010 |
Behrsing HP, Furniss MJ, Robillard KA, Tomaszewski JE, Parchment RE. In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines. Cancer Chemotherapy and Pharmacology. 65: 1083-91. PMID 19727731 DOI: 10.1007/S00280-009-1113-7 |
0.381 |
|
| 2010 |
Giaccone G, Rajan A, Kelly RJ, Gutierrez M, Kummar S, Yancey M, Ji JJ, Zhang Y, Parchment RE, Doroshow JH. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. Journal of Clinical Oncology. 28: 3027-3027. DOI: 10.1200/Jco.2010.28.15_Suppl.3027 |
0.374 |
|
| 2010 |
Ji JJ, Kummar S, Chen AP, Zhang Y, Putvtana R, Kinders RJ, Rubinstein L, Parchment RE, Tomaszewski JE, Doroshow JH. Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas. Journal of Clinical Oncology. 28: 2514-2514. DOI: 10.1200/Jco.2010.28.15_Suppl.2514 |
0.45 |
|
| 2010 |
Kinders RJ, Wang L, Kummar S, Pfister T, Parchment R, Tomaszewski J, Doroshow J. Abstract LB-286: Use of circulating tumor cells to monitor pharmacodynamic responses of patients in early-stage clinical trials Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-286 |
0.47 |
|
| 2010 |
Paoloni MC, Mazcko C, DiPaolo T, Parchment R, Kinders R, Tomaszewski J, Khanna C. Abstract 4207: Pharmacodynamic comparisons of novel cryobiopsy instrumentation compared to standard techniques through comparative oncology modeling Cancer Research. 70: 4207-4207. DOI: 10.1158/1538-7445.Am10-4207 |
0.414 |
|
| 2010 |
Zhang Y, Parchment R, Tomaszewski J, Doroshow J, Ji J. Abstract 1763: Quantitative gamma-H2AX immunoassay for pharmacodynamic monitoring anticancer cytotoxic agents Cancer Research. 70: 1763-1763. DOI: 10.1158/1538-7445.Am10-1763 |
0.415 |
|
| 2009 |
Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Molecular Cancer. 8: 47. PMID 19594950 DOI: 10.1186/1476-4598-8-47 |
0.403 |
|
| 2009 |
Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Molecular Cancer Therapeutics. 8: 1878-84. PMID 19584232 DOI: 10.1158/1535-7163.Mct-09-0016 |
0.386 |
|
| 2009 |
Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Molecular Cancer Therapeutics. 8: 1867-77. PMID 19584228 DOI: 10.1158/1535-7163.Mct-09-0274 |
0.402 |
|
| 2009 |
Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2705-11. PMID 19364967 DOI: 10.1200/Jco.2008.19.7681 |
0.478 |
|
| 2009 |
Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Investigational New Drugs. 27: 571-8. PMID 19225720 DOI: 10.1007/S10637-009-9228-6 |
0.389 |
|
| 2009 |
Pfister TD, Khin SA, Agama K, Hollingshead M, Sooryakumar D, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH, Kinders RJ. Abstract C224: A novel validated quantitative pharmacodynamic topoisomerase I covalent‐complex immunoassay Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C224 |
0.483 |
|
| 2009 |
Reinhold WC, Mergny J, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN, Pommier Y. Abstract C149: Exon array analyses across the NCI‐60 reveals potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C149 |
0.339 |
|
| 2008 |
Yang SX, Kummar S, Rubinstein L, Gutierrez M, Murgo AJ, Parchment RE, Nguyen D, Chen AP, Tomaszewski JE, Doroshow JH. Phase 0 pharmacodynamic study of poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with refractory solid tumors and lymphomas: Immunohistochemistry results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3580. PMID 27949675 DOI: 10.1200/Jco.2008.26.15_Suppl.3580 |
0.438 |
|
| 2008 |
Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6877-85. PMID 18980982 DOI: 10.1158/1078-0432.Ccr-08-0214 |
0.447 |
|
| 2008 |
Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji U, Steinberg SM, X.yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, E.tomaszewski J, et al. Designing phase 0 cancer clinical trials Clinical Cancer Research. 14: 3675-3682. PMID 18559582 DOI: 10.1158/1078-0432.Ccr-07-4560 |
0.425 |
|
| 2008 |
Doroshow JH, Parchment RE. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3658-63. PMID 18559579 DOI: 10.1158/1078-0432.Ccr-07-4562 |
0.388 |
|
| 2008 |
Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, et al. Phase 0 clinical trials: conceptions and misconceptions. Cancer Journal (Sudbury, Mass.). 14: 133-7. PMID 18536551 DOI: 10.1097/Ppo.0B013E318172D6F3 |
0.435 |
|
| 2008 |
Horn TL, Harder JB, Johnson WD, Curry PT, Parchment RE, Morrissey RL, Mellick PW, Calis KA, Gold PW, Rice KC, Contoreggi C, Charney DS, Cizza G, Glaze ER, Tomaszewski JE, et al. Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonist Toxicology. 248: 8-17. PMID 18423834 DOI: 10.1016/J.Tox.2008.03.002 |
0.352 |
|
| 2007 |
Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Molecular Interventions. 7: 325-34. PMID 18199854 DOI: 10.1124/Mi.7.6.9 |
0.442 |
|
| 2007 |
Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Molecular Cancer Therapeutics. 6: 2290-302. PMID 17699724 DOI: 10.1158/1535-7163.Mct-07-0062 |
0.445 |
|
| 2007 |
Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Compressing drug development timelines in oncology using phase '0' trials. Nature Reviews. Cancer. 7: 131-9. PMID 17251919 DOI: 10.1038/Nrc2066 |
0.392 |
|
| 2007 |
El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Investigational New Drugs. 24: 305-10. PMID 16683073 DOI: 10.1007/S10637-005-4343-5 |
0.344 |
|
| 2007 |
Kummar S, Kinders R, Gutierrez M, Rubinstein L, Parchment RE, Phillips LR, Low J, Murgo AJ, Tomaszewski JE, Doroshow JH. Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial Journal of Clinical Oncology. 25: 3518-3518. DOI: 10.1200/Jco.2007.25.18_Suppl.3518 |
0.469 |
|
| 2007 |
Parchment RE, Kinders RJ, Hollingshead M, Dancey JE, Tomaszewski JE, Doroshow JH. Technical criteria of “clinical readiness” to qualify validated pharmacodynamic (PD) assays for clinical trial use Journal of Clinical Oncology. 25: 14068-14068. DOI: 10.1200/Jco.2007.25.18_Suppl.14068 |
0.392 |
|
| 2007 |
Kinders RJ, Hollingshead M, Parchment RE, Khin S, Kaur G, Phillips L, Tomaszewski J, Doroshow J. Preclinical modeling of a phase 0 clinical trial protocol Journal of Clinical Oncology. 25: 14058-14058. DOI: 10.1200/Jco.2007.25.18_Suppl.14058 |
0.454 |
|
| 2007 |
Rubinstein LV, Steinberg SM, Kummar S, Low J, Parchment R, Kinders R, Gutierrez M, Murgo AJ, Doroshow JH, Tomaszewski J. Statistical considerations for a phase 0 trial Journal of Clinical Oncology. 25: 14038-14038. DOI: 10.1200/Jco.2007.25.18_Suppl.14038 |
0.337 |
|
| 2007 |
Ji J, Redon C, Pommier Y, Kinders R, Parchment R, Hollingshead M, Yang S, Murgo A, Tomaszewski J, Doroshow J. Poly-adeninosinediphosphate-ribose polymerase inhibitors as sensitizers for therapeutic treatments in human tumor and blood mononuclear cells Journal of Clinical Oncology. 25: 14024-14024. DOI: 10.1200/Jco.2007.25.18_Suppl.14024 |
0.434 |
|
| 2007 |
Yang SX, Nguyen D, Steinberg SM, Ji J, Parchment R, Kinders R, Kummar S, Gutierrez M, Murgo A, Tomaszewski JE, Doroshow JH. Quantitative immunohistochemical detection of gamma-H2AX in paraffin-embedded human tumor samples at National Clinical Target Validation Laboratory Journal of Clinical Oncology. 25: 10565-10565. DOI: 10.1200/Jco.2007.25.18_Suppl.10565 |
0.374 |
|
| 2006 |
Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Investigational New Drugs. 25: 147-54. PMID 17103044 DOI: 10.1007/S10637-006-9024-5 |
0.393 |
|
| 2005 |
Yoo GH, Subramanian G, Boinpally RR, Iskander A, Shehadeh N, Oliver J, Ezzat W, Piechocki MP, Ensley JF, Lin HS, Shibuya TY, Polin L, Parchment RE. An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. Archives of Otolaryngology--Head & Neck Surgery. 131: 418-29. PMID 15897421 DOI: 10.1001/Archotol.131.5.418 |
0.424 |
|
| 2005 |
Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, Ivy SP. Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemotherapy and Pharmacology. 56: 351-7. PMID 15895233 DOI: 10.1007/S00280-004-0962-3 |
0.342 |
|
| 2005 |
Vaishampayan U, Heilbrun LK, Parchment RE, Jain V, Zwiebel J, Boinpally RR, LoRusso P, Hussain M. Phase II trial of fenretinide in advanced renal carcinoma. Investigational New Drugs. 23: 179-85. PMID 15744595 DOI: 10.1007/S10637-005-5864-7 |
0.316 |
|
| 2005 |
Boinpally RR, Zhou SL, LoRusso PM, Parchment RE. Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration. Cancer Chemotherapy and Pharmacology. 55: 404-7. PMID 15592839 DOI: 10.1007/S00280-004-0862-6 |
0.335 |
|
| 2004 |
Volpe DA, LoRusso PM, Foster BJ, Parchment RE. In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis. Cancer Chemotherapy and Pharmacology. 54: 89-94. PMID 15014898 DOI: 10.1007/s00280-004-0783-4 |
0.328 |
|
| 2004 |
Gadgeel SM, Boinpally RR, Heilbrun LK, Wozniak A, Jain V, Redman B, Zalupski M, Wiegand R, Parchment R, LoRusso PM. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Investigational New Drugs. 21: 63-74. PMID 12795531 DOI: 10.1023/A:1022972427532 |
0.427 |
|
| 2004 |
Chaplen RA, Kalemkerian GP, Wozniak A, Shehadeh N, Ruckdeschel JC, Kraut MJ, Heilbrun L, Parchment R, Gadgeel SM. Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 22: 7102-7102. DOI: 10.1200/Jco.2004.22.90140.7102 |
0.368 |
|
| 2004 |
Alousi AM, Parchment R, Boinpally R, Gadgeel S, Weigand R, McCormick J, Lorusso P. Phase I clinical trial of XK469 in patients with chemo-refractory solid tumors Journal of Clinical Oncology. 22: 2020-2020. DOI: 10.1200/Jco.2004.22.14_Suppl.2020 |
0.404 |
|
| 2003 |
Zhang Y, Dawson MI, Ning Y, Polin L, Parchment RE, Corbett T, Mohamed AN, Feng KC, Farhana L, Rishi AK, Hogge D, Leid M, Peterson VJ, Zhang XK, Mohammad R, et al. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood. 102: 3743-52. PMID 12893763 DOI: 10.1182/Blood-2003-01-0108 |
0.325 |
|
| 2003 |
Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, Croera C, Gagliardi G, Foti P, Parchment R, Parent-Massin D, Schoeters G, Sibiril Y, Van Den Heuvel R, Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicological Sciences : An Official Journal of the Society of Toxicology. 75: 355-67. PMID 12883091 DOI: 10.1093/Toxsci/Kfg188 |
0.367 |
|
| 2003 |
Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, Croera C, Parchment R, Parent-Massin D, Schoeters G, Sibiri Y, Van Den Heuvel R, Gribaldo L. In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay. Alternatives to Laboratory Animals : Atla. 75-9. PMID 12513654 DOI: 10.1177/026119290203002S11 |
0.374 |
|
| 2003 |
Schneider B, Worden FP, Gadgeel SM, Hodges CM, Parchment RE, Zwiebel JA, Kraut MJ, Kalemkerian GP. P-565 Phase II study of Fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy Lung Cancer. 41: S234. DOI: 10.1200/Jco.2004.22.14_Suppl.7299 |
0.384 |
|
| 2003 |
Gadgeel SM, Shehadeh N, Kraut MJ, Wozniak A, Belzer K, Ward D, Hodges C, Parchment R, Chaplen R, Kalemkerian GP. O-110 Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (> 70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC) Lung Cancer. 41: S35. DOI: 10.1016/S0169-5002(03)91768-5 |
0.3 |
|
| 2002 |
LoRusso PM, Prakash S, Wozniak A, Flaherty L, Zalupski M, Shields A, Sands H, Parchment R, Jasti B. Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU). Investigational New Drugs. 20: 63-71. PMID 12003195 DOI: 10.1023/A:1014430216434 |
0.427 |
|
| 2002 |
Poondru S, Parchment RE, Purohit V, LoRusso P, Horwitz JP, Hazeldine ST, Polin L, Corbett T, Jasti BR. Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30. Investigational New Drugs. 20: 23-33. PMID 12003192 DOI: 10.1023/A:1014457510073 |
0.417 |
|
| 2002 |
Pessina A, Albella B, Bueren J, Brantom P, Casati S, Gribaldo L, Croera C, Gagliardi G, Foti P, Parchment R, Parent-Massin D, Sibiril Y, Van Den Heuvel R. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicology in Vitro : An International Journal Published in Association With Bibra. 15: 729-40. PMID 11698175 DOI: 10.1016/S0887-2333(01)00085-6 |
0.346 |
|
| 2001 |
Poondru S, Zhou S, Rake J, Shackleton G, Corbett TH, Parchment RE, Jasti BR. High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma. Journal of Chromatography. B, Biomedical Sciences and Applications. 759: 175-8. PMID 11499623 DOI: 10.1016/S0378-4347(01)00217-1 |
0.309 |
|
| 2001 |
Keyes KA, Segovia JC, Bueren JA, Parchment RE, Albella B. Latent hematopoietic stem cell toxicity associated with protracted drug administration. Experimental Hematology. 29: 286-94. PMID 11274755 DOI: 10.1016/S0301-472X(00)00670-6 |
0.742 |
|
| 2001 |
MacGregor JT, Collins JM, Sugiyama Y, Tyson CA, Dean J, Smith L, Andersen M, Curren RD, Houston JB, Kadlubar FF, Kedderis GL, Krishnan K, Li AP, Parchment RE, Thummel K, et al. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicological Sciences : An Official Journal of the Society of Toxicology. 59: 17-36. PMID 11134541 DOI: 10.1093/Toxsci/59.1.17 |
0.307 |
|
| 2000 |
Keyes KA, Albella B, LoRusso PM, Bueren JA, Parchment RE. Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 2474-81. PMID 10873102 |
0.746 |
|
| 1999 |
Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology. 54: 22-9. PMID 10606281 DOI: 10.1016/S0090-4295(99)00451-3 |
0.389 |
|
| 1998 |
LoRusso PM, Parchment R, Demchik L, Knight J, Polin L, Dzubow J, Behrens C, Harrison B, Trainor G, Corbett TH. Preclinical antitumor activity of XK469 (NSC 656889) Investigational New Drugs. 16: 287-296. PMID 10426660 DOI: 10.1023/A:1006206814025 |
0.453 |
|
| 1998 |
Parchment RE. Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. Environmental Health Perspectives. 541-57. PMID 9599702 DOI: 10.1289/Ehp.98106541 |
0.395 |
|
| 1993 |
Parchment RE, Huang M, Erickson-Miller CL. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicologic Pathology. 21: 241-50. PMID 8210945 DOI: 10.1177/019262339302100217 |
0.341 |
|
| Show low-probability matches. |